Impact of Patient Characteristics on Treatment Outcomes in Symptomatic Venous Thromboembolism: Results of HOKUSAI-VTE Randomized Trial Analysis
Introduction In patients with venous thromboembolism (VTE), direct oral anticoagulants (DOACs) such as edoxaban, apixaban, dabigatran, and rivaroxaban are more convenient, safer, and just as effective as vitamin K antagonists (VKAs). Limited information is known about the effects of patient characte...
Main Authors: | Ben van Hout, Emma Hawe, Alexander T. Cohen |
---|---|
Format: | Article |
Language: | English |
Published: |
Georg Thieme Verlag KG
2020-07-01
|
Series: | TH Open |
Subjects: | |
Online Access: | http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1716496 |
Similar Items
-
The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease
by: Cornelia Heleen vanOmmen, et al.
Published: (2020-07-01) -
Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK
by: Emilie Clay, et al.
Published: (2018-01-01) -
Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin
by: Ingrid M. Bistervels, et al.
Published: (2022-07-01) -
Risk Factors for Bleeding Events in Japanese Patients with Advanced Lung Cancer: Data from the Rising-VTE/NEJ037 Study
by: Keita Kawakado, et al.
Published: (2024-01-01) -
Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients
by: Song AB, et al.
Published: (2019-06-01)